Curated News
By: NewsRamp Editorial Staff
November 04, 2025
Kairos Pharma Reports 86% Clinical Benefit in Prostate Cancer Trial
TLDR
- Kairos Pharma's ENV105 shows 86% clinical benefit in prostate cancer trials, potentially creating a competitive advantage in oncology therapeutics and investor opportunities.
- ENV105 targets CD105 protein to reverse drug resistance, combining with apalutamide in Phase 2 trials with no dose-limiting toxicities and durable progression-free survival.
- This cancer treatment advancement brings hope for improved patient outcomes and quality of life for those battling advanced metastatic prostate cancer worldwide.
- Kairos Pharma's innovative antibody therapy targets cancer drug resistance mechanisms, showing promising results that could transform standard prostate cancer treatment approaches.
Impact - Why it Matters
This development represents a potential breakthrough in cancer treatment, particularly for patients with advanced metastatic prostate cancer who have limited therapeutic options. The 86% clinical benefit rate with no dose-limiting toxicities suggests ENV105 could significantly extend survival while maintaining quality of life for cancer patients. For the broader oncology field, the successful targeting of CD105 to reverse drug resistance opens new avenues for treating various cancers where resistance to standard therapies remains a major challenge. This approach could transform how multiple cancer types are treated, potentially making existing therapies more effective and durable. For investors and the healthcare industry, Kairos Pharma's progress demonstrates the growing potential of precision oncology approaches that address fundamental mechanisms of treatment resistance.
Summary
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company headquartered in Los Angeles, California, has released a comprehensive Letter to Shareholders from CEO John Yu, M.D., detailing the company's significant 2025 achievements and strategic outlook for 2026. The announcement highlights groundbreaking interim results from the Phase 2 clinical trial of ENV105, the company's lead therapeutic candidate, when used in combination with apalutamide for treating advanced metastatic prostate cancer. The data revealed remarkable clinical benefit in 86% of treated patients, demonstrating durable progression-free survival with no dose-limiting toxicities. These promising findings were presented at the prestigious European Society for Medical Oncologists Meeting, suggesting that ENV105 may significantly extend the effectiveness of standard care while maintaining excellent tolerability profiles. Kairos continues to actively recruit patients across leading U.S. cancer centers, with enrollment expected to reach 100 participants as the trial progresses.
ENV105 represents a novel approach to cancer treatment, targeting CD105 – a protein identified as a key driver of resistance to various cancer therapies. The company's innovative strategy focuses on overcoming drug resistance and immune suppression in cancer through advanced structural biology. When standard cancer treatments are administered, elevation of CD105 often occurs, leading to treatment resistance and disease relapse. ENV105 aims to reverse this resistance mechanism by specifically targeting CD105, thereby restoring the effectiveness of standard therapies across multiple cancer types. Beyond the current Phase 2 trial for castrate-resistant prostate cancer, ENV105 is also undergoing Phase 1 clinical evaluation for lung cancer, addressing significant unmet medical needs in oncology. The company's newsroom and additional resources are available through the InvestorBrandNetwork, which provides specialized communications and distribution services through its Dynamic Brand Portfolio, including advanced wire-grade press release syndication and comprehensive corporate communications solutions.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma Reports 86% Clinical Benefit in Prostate Cancer Trial
